# Applied Therapeutics Announces Key Leadership Appointments
Canonical URL: https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-key-leadership-appointments
Ticker: APLT
Company: Applied Therapeutics
Source: Applied Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.appliedtherapeutics.com
## Summary

Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhD Dottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.

## Article Body
Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhD Dottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.
## Recent Company News
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-acceptance-of-late-breaking-abstract-for-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports First Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-first-quarter-2025-financial-results) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-presents-full-12-month-clinical-results-and-new-topline-data-from-inspire-phase-2-3-trial-of-govorestat-in-cmt-sord-in-late-breaking-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Key Leadership Appointments](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-key-leadership-appointments) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports Second Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-second-quarter-2025-financial-results) — Source: Applied Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)